Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 11/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | ETV6 | P41212 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | ROS1 | P08922 | 3/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL29173289 | 0.97 | EML4 (0.40) | EML4ALKEGFRLCKJAK3 | |
| Formic Acid SCHEMBL30205508 | 0.97 | EML4 (0.40) | EML4ALKEGFRLCKJAK3 | |
| SCHEMBL29173442 | 0.92 | EGFR (0.40) | EML4ALKEGFRJAK3FLT3 | |
| SCHEMBL24944460 | 0.86 | EML4 (0.51) | EML4ALKEGFRLCKJAK3 | |
| SCHEMBL30205535 | 0.86 | EML4 (0.51) | EML4ALKEGFRLCKJAK3 | |
| SCHEMBL24943828 | 0.84 | CDK2 (0.37) | LCKJAK3MAP4K1SYK | |
| SCHEMBL29173534 | 0.84 | ALK (0.36) | ALKEGFRJAK3AXLSYK | |
| SCHEMBL31577227 | 0.84 | JAK2 (0.36) | EGFRJAK3FLT3MAP4K1 | |
| SCHEMBL24943823 | 0.83 | CAMK2D (0.41) | EML4ALKEGFRLCKJAK3 | |
| SCHEMBL30205967 | 0.83 | JAK3 (0.43) | ALKEGFRLCKJAK3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |